

MedicaNatumin AB (publ) announces positive results from clinical trial of foot cream

MedicaNatumin AB has conducted a clinical trial to evaluate the treatment of foot fungus, Tinea Pedis Interdigitalis, with the company's proprietary foot cream at three clinics in Sweden: Örebro, Skövde and Gothenburg. The study was coordinated by Dr. Martin Lundvall, specialist in general medicine at Region Örebro County.

A total of 46 study participants were included from October 2018 to September 2019. The purpose of the clinical trial was to document a reduction of clinical symptoms of mild to moderate foot fungus by at least 33%. The study results showed a reduction well above the set target. In addition, the participants' quality of life was examined through a questionnaire that also showed very good results. The final study results will be presented in the form of a publication in a scientific journal when all data is compiled.

"It is very important to continuously follow up treatment with clinical research, and it is gratifying that MedicaNatumin has chosen to do this in the form of a well-constructed clinical multi-centre study," says Dr. Martin Lundvall, principle investigator.

The foot cream is a patented CE-labelled medical device that is intended for the treatment of foot fungus, heel cracks and calluses as well as dry feet. The product is sold in Sweden, Norway and on the remaining European market under the Salvequick Foot Rescue brand.

Ulrika Albers, CEO MedicaNatumin, "With very strong study results, where the primary endpoint was achieved with a good margin, we have continued to document the clinical effects of our foot cream. The study is part of MedicaNatumin's clinical strategy for our medical devices in order to meet the increasing demands of the new EU medical device regulation (MDR) regulation".

For more information contact:

Ulrika Albers, VD
Ulrika.albers@medicanatumin.se

This information is information that MedicaNatumin AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on November 15th, 2019.

This is MedicaNatumin

MedicaNatumin is a Scandinavian self-care Group based in Habo/Jönköping, Sweden. The Group focuses on developing, producing and marketing healthcare products based on innovative ingredients and solid scientific research. Our goal is to contribute to a positive health trend and to provide improved quality of life through products that treat or support the different functions of the human body. Many of our products are manufactured in our Swedish production unit in accordance with the applicable regulations for the different product types. We also develop and manufacture products on behalf of external partners. Our products are sold through health care chains, pharmacies and online sales channels, primarily in the Nordic market, but also to consumers around the world through agencies and marketing distributors

MedicaNatumin AB (publ) is listed on Nordic Growth Market (NGM) Nordic SME.